Abstract: Foamed plastic structures that include one or more foamed plastic bodies containing a polymer matrix that includes one or more polymers formed by polymerizing a monomer mixture formed by polymerizing a monomer mixture containing vinyl aromatic monomers using a polymerization initiator having a structure corresponding to: R(Y)n where R is a C2 to C32 linear, branched, and/or cyclic aliphatic and/or aromatic group that can also include one or more atoms selected from oxygen, nitrogen, halides, silicon and sulfur, Y is a group that can generate a free radical capable of initiating polymerization of the monomers in the monomer mixture; and n is from 2 to 6. The structures formed can include, as non-limiting examples, pallets, containers, stackable containers, produce boxes, seafood shipping containers, geofoam blocks, and insulated concrete forms.

Abstract: A method of forming an integrated circuit is provided. The method includes performing a multiple-time flash anneal process to a wafer, wherein the multiple-time flash anneal process comprises preheating the wafer to a first preheat temperature; performing a first flash on the wafer with a first flash energy; preheating the wafer to a second preheat temperature; and performing a second flash on the wafer with a second flash energy.

Abstract: A method of forming a gate dielectric layer includes forming a gate dielectric layer over a substrate. The gate dielectric layer is processed with carbon-containing ions. The gate dielectric layer is thermally processed, thereby providing the gate dielectric layer with a level of carbon between about 1 atomic % and about 20 atomic %.

Abstract: In a communication network that provides a path through a cable IP network between sending and receiving terminals residing on respective networks (e.g., an HFC, and/or PSTN network) controlled by different network managers or service providers, a controller hands off control of service access of the terminals between the service providers. Subscriber terminals may include broadband telephony interfaces, cable modems, or multimedia terminal adapters. To effect hand-off control, configurable modules of the terminals enable them to respond directly to a network manager (e.g., cable modem termination system or call management server) according to instructions supplied by the controller based either on subscriber authorization, database information, call type, dialing plan, and/or other parameters. Transfer of call control may also occur on a call-by-call basis.

Abstract: A bicycle lock holding apparatus for fastening to a bicycle frame that may be installed and removed quickly to hold a bicycle lock includes a holding structure for fastening to the bicycle frame and a coupling structure for coupling with the lock. The holding structure has an anchor seat with one end fastening to a latch dock. Through an anchor plate coupling with the anchor seat, the latch dock may be turned to change the direction of a wedge trough formed on one end thereof. The coupling structure has a latch section latching in the wedge trough with two extendable button extended from two sides to insert into apertures formed on two sides of the wedge trough so that the coupling structure and the holding structure form a firm coupling.

Abstract: The present disclosure includes method, system, apparatus, and indicator embodiments. For example, one system for monitoring orthodontic treatment includes an appliance for placement over one or more teeth and multiple wear indicators including at least a first wear indicator having a first wear rate and a second wear indicator that has a second wear rate that is different from the first.

Abstract: Novel TNF receptor death domain (“TNF-R1-DD”) ligand proteins are disclosed. Polynucleotides encoding the TNF-R1-DD ligand protein are also disclosed, along with vectors, host cells, and methods of making the TNF-R1-DD ligand protein. Pharmaceutical compositions containing the TNF-R1-DD ligand protein, methods of treating inflammatory conditions, and methods of inhibiting TNF-R death domain binding are also disclosed. Methods of identifying inhibitors of TNF-R death domain binding and inhibitors identified by such methods are also disclosed.

Abstract: Novel TNF receptor death domain (“TNF-R1-DD”) ligand proteins are disclosed. Polynucleotides encoding the TNF-R1-DD ligand protein are also disclosed, along with vectors, host cells, and methods of making the TNF-R1-DD ligand protein. Pharmaceutical compositions containing the TNF-R1-DD ligand protein, methods of treating inflammatory conditions, and methods of inhibiting TNF-R death domain binding are also disclosed. Methods of identifying inhibitors of TNF-R death domain binding and inhibitors identified by such methods are also disclosed.

Abstract: A vehicle tire lock to prevent vehicle tires from being stolen includes a core seat, a upper duct, a lock assembly and a lower duct. The upper duct and the lower duct are extendable to run though the tires. Locking and unlocking operations may be performed through the core seat and lock assembly to prevent the vehicle tires from being stolen.

Abstract: A bicycle lock holding apparatus for fastening to a bicycle frame that may be installed and removed quickly to hold a bicycle lock includes a holding structure for fastening to the bicycle frame and a coupling structure for coupling with the lock. The holding structure has an anchor seat with one end fastening to a latch dock. Through an anchor plate coupling with the anchor seat, the latch dock may be turned to change the direction of a wedge trough formed on one end thereof. The coupling structure has a latch section latching in the wedge trough with two extendable button extended from two sides to insert into apertures formed on two sides of the wedge trough so that the coupling structure and the holding structure form a firm coupling.

Abstract: Systems and methods are disclosed for intra-oral delivery of drugs.

Abstract: Compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of one or more mitotic kinesins are disclosed.

Abstract: An apparatus for monitoring orthodontic treatment compliance includes an appliance adapted to be worn over one or more teeth; and a compliance indicator mounted on the appliance to indicate compliance.

Abstract: The present invention relates to a method for disrupting cultured cells that lack a cell wall, the method comprising passing the cells suspended in a suspension fluid through a nozzle at a low pressure, wherein the outflow of the nozzle does not impinge on the outflow of a second nozzle if multiple nozzles are present.

Abstract: Novel TNF receptor death domain (“TNF-R1-DD”) ligand proteins are disclosed. Polynucleotides encoding the TNF-R1-DD ligand protein are also disclosed, along with vectors, host cells, and methods of making the TNF-R1-DD ligand protein. Pharmaceutical compositions containing the TNF-R1-DD ligand protein, methods of treating inflammatory conditions, and methods of inhibiting TNF-R death domain binding are also disclosed. Methods of identifying inhibitors of TNF-R death domain binding and inhibitors identified by such methods are also disclosed.

Abstract: Novel TNF receptor death domain (“TNF-R1-DD”) ligand proteins are disclosed. Polynucleotides encoding the TNF-R1-DD ligand protein are also disclosed, along with vectors, host cells, and methods of making the TNF-R1-DD ligand protein. Pharmaceutical compositions containing the TNF-R1-DD ligand protein, methods of treating inflammatory conditions, and methods of inhibiting TNF-R death domain binding are also disclosed. Methods of identifying inhibitors of TNF-R death domain binding and inhibitors identified by such methods are also disclosed.

Abstract: Novel TNF receptor death domain ("TNF-R1-DD") ligand proteins are disclosed. Polynucleotides encoding the TNF-R1-DD ligand protein are also disclosed, along with vectors, host cells, and methods of making the TNF-R1-DD ligand protein. Pharmaceutical compositions containing the TNF-R1-DD ligand protein, methods of treating inflammatory conditions, and methods of inhibiting TNF-R death domain binding are also disclosed. Methods of identifying inhibitors of TNF-R death domain binding and inhibitors identified by such methods are also disclosed.

Abstract: Novel TNF receptor death domain ("TNF-R1-DD") ligand proteins are disclosed. Polynucleotides encoding the TNF-R1-DD ligand protein are also disclosed, along with vectors, host cells, and methods of making the TNF-R1-DD ligand protein. Pharmaceutical compositions containing the TNF-R1-DD ligand protein, methods of treating inflammatory conditions, and methods of inhibiting TNF-R death domain binding are also disclosed. Methods of identifying inhibitors of TNF-R death domain binding and inhibitors identified by such methods are also disclosed.

Abstract: Novel TNF receptor death domain ("TNF-R1-DD") ligand proteins are disclosed. Polynucleotides encoding the TNF-R1-DD ligand protein are also disclosed, along with vectors, host cells, and methods of making the TNF-R1-DD ligand protein. Pharmaceutical compositions containing the TNF-R1-DD ligand protein, methods of treating inflammatory conditions, and methods of inhibiting TNF-R death domain binding are also disclosed. Methods of identifying inhibitors of TNF-R death domain binding and inhibitors identified by such methods are also disclosed.

Abstract: Novel TNF receptor death domain ("TNF-R1-DD") ligand proteins are disclosed. Polynucleotides encoding the TNF-R1-DD ligand protein are also disclosed, along with vectors, host cells, and methods of making the TNF-R1-DD ligand protein. Pharmaceutical compositions containing the TNF-R1-DD ligand protein, methods of treating inflammatory conditions, and methods of inhibiting TNF-R death domain binding are also disclosed. Methods of identifying inhibitors of TNF-R death domain binding and inhibitors identified by such methods are also disclosed.